Deceased donors with multidrug-resistant organisms: implications and future directions

Pouch, Stephanie M.; Ison, Michael G.

doi:10.1097/mot.0000000000000991

Cited by 3 publications

(1 citation statement)

References 39 publications

(72 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the epidemiology varies markedly among different geographical regions, risk factors of prolonged (> 7 days) ICU stay, vasopressor support, and cardiopulmonary resuscitation increases colonization with multidrug-resistant organisms (MDRO) including extended-spectrum β-lactamase -producing Enterobacteriaceae (ESBL-E) and carbapenem-resistant organisms (CRO) in donors [ 4 ]. The current study suggests that MDRO or CRO may significantly contribute to the burden of bacterial DDI [ 5 , 6 ]. Lung transplant recipients appear to be disproportionately affected, potentially due to the high frequency of MDRO colonization of the donor respiratory tract [ 7 , 8 ].…”

Section: Introductionmentioning

confidence: 99%

Real-time, random-access organ screening for carbapenem-resistant organisms (CRO) reduces CRO-associated, donor-derived infection mortality in lung transplant recipients

Zhou,

Shen,

Shi

et al. 2023

Infection

View full text Add to dashboard Cite

Purpose Donor-derived infection (DDI) has become an important factor affecting the prognosis of lung transplantation patients. The risks versus benefits of using donor organs infected with multidrug-resistant organisms (MDRO), especially carbapenem-resistant organisms (CRO), are frequently debated. Traditional microbial culture and antimicrobial susceptibility testing at present fail to meet the needs of quick CRO determination for donor lungs before acquisition. In this study, we explored a novel screening method by using Xpert® Carba-R assay for CRO in donor lungs in a real-time manner to reduce CRO-associated DDI mortality. Methods This study was registered on chictr.org.cn (ChiCTR2100053687) on November 2021. In the Xpert Carba-R screening group, donor lungs were screened for CRO infection by the Xpert Carba-R test on bronchoalveolar fluid (BALF) before acquisition. If the result was negative, donor lung acquisition and subsequent lung transplantation were performed. In the thirty-five potential donors, nine (25.71%) with positive Xpert Carba-R results in BALF were declined for lung transplantation. Twenty-six recipients and the matching CRO-negative donor lungs (74.29%) were included in the Xpert Carba-R screening group. In the control group, nineteen recipients underwent lung transplants without Xpert Carba-R screening. The incidence and mortality of CRO-associated DDI were collected and contrasted between the two groups. Results Multivariate analysis showed that CRO-related death due to DDI within 60 days was significantly lower in the Xpert Carba-R screening group than that in the control group (OR = 0.05, 95% CI 0.003–0.74, p = 0.03). Conclusion Real-time CRO screening of donor lungs before transplantation at the point of care by the Xpert Carba-R helps clinicians formulate lung transplantation strategies quickly and reduces the risk of subsequent CRO infection improving the prognosis of lung transplantation.

show abstract

Section: Introductionmentioning

confidence: 99%

Real-time, random-access organ screening for carbapenem-resistant organisms (CRO) reduces CRO-associated, donor-derived infection mortality in lung transplant recipients

Zhou,

Shen,

Shi

et al. 2023

Infection

View full text Add to dashboard Cite

show abstract

Donor-derived carbapenem-resistant gram-negative bacterial infections in solid organ transplant recipients: Active surveillance enhances recipient safety

Mularoni,

Cona,

Campanella

et al. 2024

American Journal of Transplantation

View full text Add to dashboard Cite

Broad-Spectrum Antibiotic Resistance in septic patients in an Ecuadorian Intensive Care Unit of the Hospital Provincial General Docente of Riobamba

Yepez,

Romero,

Aldaz

et al. 2024

View full text Add to dashboard Cite

Bacterial sepsis is one of the most frequent pathologies treated in an intensive care unit. It represents a significant cause of morbidity and mortality at the hospital level, even more so if resistance to antibacterials used as first-line treatment is present. The present study aims to determine the prevalence of Broad-Spectrum Antibiotic Resistance in adult patients over 18 years of age in the Intensive Care Unit of the Hospital Provincial General Docente of Riobamba, Ecuador, in 2023. This is an original, observational, cross-sectional study. The main results are the prevalence of Broad-Spectrum Antibiotic Resistance of 21.9% (95% CI 6.73%-37.02%) and the prevalence of bacterial sepsis of 16% (95% CI 12.2%-19.7%). It is concluded that the prevalence of bacterial sepsis and resistance to broad-spectrum antibacterials is high in the Intensive Care Unit, where the bacteria found most frequently and confer the highest percentage of resistance to septic patients are K. pneumoniae, E. coli, and P. aeruginosa. Keywords: Drug Resistance, Microbial, sepsis; shock, septic

show abstract

Deceased donors with multidrug-resistant organisms: implications and future directions

Cited by 3 publications

References 39 publications

Real-time, random-access organ screening for carbapenem-resistant organisms (CRO) reduces CRO-associated, donor-derived infection mortality in lung transplant recipients

Real-time, random-access organ screening for carbapenem-resistant organisms (CRO) reduces CRO-associated, donor-derived infection mortality in lung transplant recipients

Donor-derived carbapenem-resistant gram-negative bacterial infections in solid organ transplant recipients: Active surveillance enhances recipient safety

Broad-Spectrum Antibiotic Resistance in septic patients in an Ecuadorian Intensive Care Unit of the Hospital Provincial General Docente of Riobamba

Contact Info

Product

Resources

About